BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33916719)

  • 1. Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer.
    Sengal AT; Smith D; Rogers R; Snell CE; Williams ED; Pollock PM
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.
    Sengal AT; Smith D; Snell CE; Leung S; Talhouk A; Williams ED; McAlpine JN; Pollock PM
    J Pathol Clin Res; 2022 Nov; 8(6):521-537. PubMed ID: 35866380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.
    Sengal AT; Patch AM; Snell CE; Smith DS; Leung SCY; Talhouk A; Williams ED; McAlpine JN; Pollock PM
    Clin Cancer Res; 2020 Sep; 26(17):4569-4580. PubMed ID: 32414751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia.
    Zhang X; Zhao X; Wang C; Lu S; Wang Y; He Y; Wang J; Shen D
    Oncol Lett; 2023 Feb; 25(2):52. PubMed ID: 36644134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management.
    Nwanodi O
    Healthcare (Basel); 2017 Jul; 5(3):. PubMed ID: 28698465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
    Dolapcioglu K; Boz A; Baloglu A
    Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
    Karimi-Zarchi M; Dehghani-Firoozabadi R; Tabatabaie A; Dehghani-Firoozabadi Z; Teimoori S; Chiti Z; Miratashi-Yazdi A; Dehghani A
    Clin Exp Obstet Gynecol; 2013; 40(3):421-4. PubMed ID: 24283179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review.
    Wei J; Zhang W; Feng L; Gao W
    Medicine (Baltimore); 2017 Sep; 96(37):e8034. PubMed ID: 28906392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
    El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
    Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.
    Minig L; Franchi D; Boveri S; Casadio C; Bocciolone L; Sideri M
    Ann Oncol; 2011 Mar; 22(3):643-649. PubMed ID: 20876910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
    Gallos ID; Devey J; Ganesan R; Gupta JK
    Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.